We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-5.73%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.16B
AUM Growth
+$104M
Cap. Flow
-$1.09B
Cap. Flow %
-34.59%
Top 10 Hldgs %
35.35%
Holding
97
New
14
Increased
28
Reduced
11
Closed
11

Top Buys

Rank Stock Value
1
BCYC
Bicycle Therapeutics
BCYC
+$29.5M
2
ETNB
89bio
ETNB
+$26.7M
3
IMCR icon
Immunocore
IMCR
+$26M
4
TMO icon
Thermo Fisher Scientific
TMO
+$25.8M
5
INSP icon
Inspire Medical Systems
INSP
+$25.3M

Top Sells

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$47.8M
2
BIIB icon
Biogen
BIIB
+$34.7M
3
ALGN icon
Align Technology
ALGN
+$34.1M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$30.1M
5
GKOS icon
Glaukos
GKOS
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 51.8%
2 Miscellaneous 47.89%
3 Consumer Staples 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LUNG icon
51
Pulmonx
LUNG
$102M
$10.2M 0.32%
988,559
-10,803
-1% -$125K
SKIN icon
52
SkinHealth Systems
SKIN
$89.1M
$9.79M 0.31%
+1,626,236
New +$11.4M
AMGN icon
53
Amgen
AMGN
$234B
$9.73M 0.31%
+36,200
New +$9.03M
SGEN
54
DELISTED
Seagen Inc. Common Stock
SGEN
$9.02M 0.28%
42,497
– –
KRYS icon
55
Krystal Biotech
KRYS
$10.4B
$8.99M 0.28%
77,497
-163,902
-68% -$20M
REPL icon
56
Replimune Group
REPL
$1.46B
$8.34M 0.26%
487,520
– –
AGEN
57
Agenus
AGEN
$345M
$7.13M 0.23%
315,352
+80,455
+34% +$2.28M
RYZB
58
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$6.17M 0.19%
+277,778
New +$5.83M
ALXO icon
59
ALX Oncology
ALXO
$277M
$6M 0.19%
1,249,900
– –
ADPT icon
60
Adaptive Biotechnologies
ADPT
$4.02B
$5.27M 0.17%
967,690
+319,239
+49% +$2.11M
ACRS icon
61
Aclaris Therapeutics
ACRS
$885M
– –
-2,901,194
Closed -$30.1M
ATEC icon
62
Alphatec Holdings
ATEC
$1.46B
– –
-25,431
Closed -$457K
BIIB icon
63
Biogen
BIIB
$32.3B
– –
-121,942
Closed -$34.7M
CRNX icon
64
Crinetics Pharmaceuticals
CRNX
$9B
– –
-650,312
Closed -$11.7M
ESPR
65
DELISTED
Esperion Therapeutics
ESPR
– –
-895,949
Closed -$1.25M
MRUS
66
DELISTED
Merus
MRUS
$0 ﹤0.01%
1,901,337
+358,175
+23% +$8.69M
NUVB icon
67
Nuvation Bio
NUVB
$2.34B
– –
-4,122,900
Closed -$7.42M
RYTM icon
68
Rhythm Pharmaceuticals
RYTM
$7.38B
– –
-843,087
Closed -$13.9M
SLRN
69
DELISTED
ACELYRIN
SLRN
– –
-500,000
Closed -$10.4M
VIR icon
70
Vir Biotechnology
VIR
$1.83B
– –
-728,549
Closed -$17.9M
MRTX
71
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-240,625
Closed -$8.69M
DICE
72
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-1,029,901
Closed -$47.8M
1 2
3

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q3 2023 Portfolio in Review

As of Q3 2023, Braidwell held 97 positions worth $3.16B, up 3.4% from $3.06B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Braidwell withdrew a net $1.09B in Q3 2023, closing 11 positions and reducing 11 holdings. Its most notable exit was DICE Therapeutics, Inc. Common Stock, an estimated $47.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 54% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Bicycle Therapeutics worth $25.9M.

  • Braidwell's largest Q3 2023 buy was Bicycle Therapeutics: 1,289,872 shares worth $25.9M.
  • Braidwell added most to Immunocore in Q3 2023, an estimated $26M increase.
  • Braidwell's biggest Q3 2023 reduction was Align Technology, cutting an estimated $34.1M.
  • Braidwell fully exited DICE Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $47.8M.
  • Braidwell's ten largest holdings make up 35% of its $3.16B portfolio in Q3 2023.
  • Braidwell opened 14 new positions and closed 11 in Q3 2023.
  • Braidwell's portfolio value rose 3.4% quarter-over-quarter to $3.16B.

Based on Braidwell's 13F filing for Q3 2023, filed 14 Nov 2023.